132 related articles for article (PubMed ID: 2679476)
1. Prostatic complications of testosterone replacement therapy.
Jackson JA; Waxman J; Spiekerman AM
Arch Intern Med; 1989 Oct; 149(10):2365-6. PubMed ID: 2679476
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer following testosterone replacement in Klinefelter syndrome.
Bydder SA; Joseph DJ; Weinstein S; Stuckey BG
ANZ J Surg; 2007; 77(1-2):93-4. PubMed ID: 17295832
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
6. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
Morgunov LIu; Vertkin AL; Pushkar' DIu
Urologiia; 2007; (5):49-51. PubMed ID: 18254226
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer in men using testosterone supplementation.
Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer in a hypogonadal male receiving androgen supplementation.
Ferri M; Norman RW
Can J Urol; 2000 Jun; 7(3):1055-6. PubMed ID: 11118282
[TBL] [Abstract][Full Text] [Related]
10. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
11. Testosterone therapy in the ageing male: what about the prostate?
Schultheiss D; Machtens S; Jonas U
Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer after exogenous testosterone treatment for impotence.
Loughlin KR; Richie JP
J Urol; 1997 May; 157(5):1845. PubMed ID: 9112543
[No Abstract] [Full Text] [Related]
13. Testosterone replacement therapy and prostate risks: where's the beef?
Morgentaler A
Can J Urol; 2006 Feb; 13 Suppl 1():40-3. PubMed ID: 16526980
[TBL] [Abstract][Full Text] [Related]
14. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy in hypogonadal men and prostate cancer risk.
Kirby R; Gould D
BJU Int; 2005 Sep; 96(4):471-2. PubMed ID: 16104891
[No Abstract] [Full Text] [Related]
17. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
18. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
19. [Testosterone substitution in patients with hypogonadism].
Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
